Frontiers in drug delivery最新文献

筛选
英文 中文
Formulation and characterization of solid dispersion adsorbate of Candesartan Cilexetil: in vitro dissolution and in vivo performance. 坎地沙坦西蕾蒂酯固体分散吸附剂的配方及表征:体外溶出度及体内性能。
IF 4.4
Frontiers in drug delivery Pub Date : 2026-10-26 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1975209
Harshad Makwana, Anjali Patel, Manisha Lalan, Meenakshi Patel, Nirmal Shah, Bhavin Vyas, Bhupendra Prajapati, Pranav Shah
{"title":"Formulation and characterization of solid dispersion adsorbate of Candesartan Cilexetil: in vitro dissolution and in vivo performance.","authors":"Harshad Makwana, Anjali Patel, Manisha Lalan, Meenakshi Patel, Nirmal Shah, Bhavin Vyas, Bhupendra Prajapati, Pranav Shah","doi":"10.3389/fddev.2026.1975209","DOIUrl":"10.3389/fddev.2026.1975209","url":null,"abstract":"<p><strong>Introduction: </strong>Candesartan Cilexetil (CC) is a non-peptide angiotensin II type 1 receptor antagonist widely used in the treatment of hypertension. However, CC has poor aqueous solubility (0.006 ± 0.002 mg/mL), low oral bioavailability (15%) and undergoes significant first-pass metabolism.</p><p><strong>Methods: </strong>Candesartan Cilexetil Solid Dispersion adsorbate (CC-SDAs) was formulated by the fusion method, employing polyethylene glycol (PEG) 4000 as a hydrophilic carrier and Neusilin® US2 as an adsorbent, to improve the solubility, dissolution, and oral bioavailability of CC. The formulation was optimized using a 3<sup>2</sup> factorial design.</p><p><strong>Results and discussion: </strong>The optimized SDA formulation exhibited the following properties: Carr's index (9.86 ± 0.09%), Hausner's ratio (1.10 ± 0.16) and angle of repose (26.00 ± 0.19°), which shows improved flow property. DSC and XRD studies confirmed the conversion of the crystalline drug into an amorphous form. The optimized SDA formulation achieved %CDR of 90.41 ± 0.95% at Q30 min, demonstrating a marked improvement in in vitro dissolution compared to the pure drug (%CDR of 57.20 ± 3.78% at Q30 min). Furthermore, in vivo pharmacokinetic studies revealed a 2.02-fold enhanced oral bioavailability of CC from the SDA formulation compared to the CC suspension. Therefore, the SDA technique proves to be a promising approach for enhancing the solubility and dissolution of poorly water-soluble drugs.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1975209"},"PeriodicalIF":4.4,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13745488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149382115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intranasal delivery of regenerative biologics for neurological disorders: a systematic review of clinical studies. 鼻内给药再生生物制剂治疗神经系统疾病:临床研究的系统回顾。
IF 4.4
Frontiers in drug delivery Pub Date : 2026-10-16 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1969111
Umm E Habiba, Iqra Sarwar, Sabiha Shamim, David Lawrence Greene
{"title":"Intranasal delivery of regenerative biologics for neurological disorders: a systematic review of clinical studies.","authors":"Umm E Habiba, Iqra Sarwar, Sabiha Shamim, David Lawrence Greene","doi":"10.3389/fddev.2026.1969111","DOIUrl":"10.3389/fddev.2026.1969111","url":null,"abstract":"<p><strong>Introduction: </strong>Intranasal delivery is a minimally invasive route for administering regenerative biologics to the central nervous system while bypassing the blood-brain barrier. Human clinical evidence for this approach across neurological disorders remains dispersed across multiple disease areas, biologic classes, dosing frameworks, and delivery methods, limiting field-level synthesis. This study was conducted to systematically evaluate the safety, dosing characteristics, delivery method heterogeneity, and disease-specific direction of effect of intranasal regenerative biologics, including mesenchymal stromal cells (MSCs), neural stem cells (NSCs), exosomes, secretome and conditioned medium, breast milk-derived biologic preparations, and related regenerative products, in patients with neurological disorders.</p><p><strong>Methodology: </strong>An International Prospective Register of Systematic Reviews (PROSPERO)-registered systematic review was conducted and reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines, with synthesis performed in accordance with Synthesis Without Meta-Analysis (SWiM) recommendations. PubMed, Google Scholar, <i>ClinicalTrials.gov</i>, and ChiCTR were searched from January 2015 to August 2026. Risk of Bias (RoB) was assessed using study design-appropriate validated tools, including Cochrane RoB 2 and Risk of Bias In Non-randomized Studies - of Interventions (ROBINS-I) and methodological quality of uncontrolled studies was appraised using the Joanna Briggs Institute (JBI) Critical Appraisal Checklists for Case Series and Case Reports.</p><p><strong>Results: </strong>Sixteen publications comprising 18 patient cohorts across 12 neurological conditions were included. No treatment-related serious adverse events were reported. Most cohorts showed clinical improvement, while one reported stabilization, though the predominantly uncontrolled designs mean placebo response and natural disease history cannot be ruled out. However, the biologic class was strongly confounded by disease indication, dosing was heterogeneous and non-comparable, and five delivery techniques were used.</p><p><strong>Discussion: </strong>By integrating clinical evidence across biologic classes and neurological disorders, this review defines the current safety landscape, highlights major methodological gaps, and provides a framework for standardized future intranasal regenerative trials.</p><p><strong>Conclusion: </strong>Adequately powered, standardized, and controlled trials are required before clinical adoption can be considered.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1969111"},"PeriodicalIF":4.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149302502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maleimide availability in thiol-maleimide peptide conjugation on PEGylated liposomes: a reactive-site accounting framework illustrated using hepatic drug-delivery systems. 聚乙二醇化脂质体上巯基-马来酰亚胺肽偶联的马来酰亚胺可用性:使用肝脏给药系统说明的反应位点会计框架。
IF 4.4
Frontiers in drug delivery Pub Date : 2026-10-13 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1964437
Kashif Maroof, Rükan Genç
{"title":"Maleimide availability in thiol-maleimide peptide conjugation on PEGylated liposomes: a reactive-site accounting framework illustrated using hepatic drug-delivery systems.","authors":"Kashif Maroof, Rükan Genç","doi":"10.3389/fddev.2026.1964437","DOIUrl":"https://doi.org/10.3389/fddev.2026.1964437","url":null,"abstract":"<p><p>Peptide-targeted PEGylated liposomes are a widely investigated active-targeting strategy for hepatocellular carcinoma (HCC) and other hepatic indications. A critical but underreported formulation variable is effective maleimide availability: the number of outward-facing, unhydrolysed, sterically accessible maleimide groups present when peptide thiols are coupled. In the seven hepatic systems examined, authors often report nominal lipid or peptide input without measuring reactive sites, conjugation efficiency, or final surface density. Hydrolysis, steric access, bilayer orientation, and peptide-thiol oxidation are individually well-established features of thiol-maleimide chemistry; the contribution of this Perspective is not to identify these phenomena but to integrate them into a quantitative accounting framework that links nominal input to biological outcome. We therefore propose a reactive-site accounting framework that separates six distinct quantities often conflated in practice: nominal maleimide input (the formulation's stated lipid composition), reactive maleimide (the outward-facing, unhydrolyzed fraction actually present at coupling), available peptide thiol (the free-thiol fraction remaining after synthesis, reduction or thiolation, and handling), conjugation efficiency (the proportion of input peptide that is actually conjugated), final conjugated ligand density (molecules per particle), and biologically accessible ligand density (the fraction capable of engaging its receptor in the biological milieu). Route selection, such as distinguishing maleimide-lipid pre-incorporation, post-insertion of a lipid conjugate, and direct coupling on preformed liposomes, should be evaluated experimentally rather than assumed. The chemical limitations underlying this framework are not specific to hepatic targeting; the seven hepatic systems examined here serve as an illustrative case set for a broader reporting problem in thiol-maleimide functionalization of nanocarriers. Reporting these measures would make density-response relationships easier to interpret and peptide-liposome studies, hepatic and otherwise, easier to reproduce.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1964437"},"PeriodicalIF":4.4,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metal-organic and covalent organic frameworks for precision drug delivery: a precision-by-design evidence framework for biologically accountable nanomedicine. 精确给药的金属有机和共价有机框架:生物学上负责的纳米医学的精确设计证据框架。
IF 4.4
Frontiers in drug delivery Pub Date : 2026-10-13 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1970554
Xinwei Li, Haonan Zhang, Ruidong Ding, Feng Wang
{"title":"Metal-organic and covalent organic frameworks for precision drug delivery: a precision-by-design evidence framework for biologically accountable nanomedicine.","authors":"Xinwei Li, Haonan Zhang, Ruidong Ding, Feng Wang","doi":"10.3389/fddev.2026.1970554","DOIUrl":"https://doi.org/10.3389/fddev.2026.1970554","url":null,"abstract":"<p><strong>Introduction: </strong>Metal-organic frameworks and covalent organic frameworks offer a rare opportunity to design drug carriers from molecular building blocks upward. Yet high loading capacity and stimulus-responsive release alone do not constitute precision delivery.</p><p><strong>Methods: </strong>We critically synthesized evidence on MOF and COF pore-level cargo interactions, framework and surface engineering, endogenous and externally triggered release, active targeting, biomimetic coatings, nanozyme activity and theranostic integration. Precision delivery was decomposed into five evidence-qualified dimensions: material, spatial, temporal, mechanistic and translational precision.</p><p><strong>Results: </strong>The evidence supports the complementary strengths of the two families across small-molecule, protein, nucleic-acid, gas and catalytic therapies. Direct evidence is strongest for individual component technologies, selected antibody-targeted systems and two-component hybrids. Recurrent evidence gaps include incomplete particle characterization in biological media, reliance on total-tissue accumulation rather than cell-specific delivery, and insufficient separation of carrier degradation from drug release.</p><p><strong>Discussion: </strong>A framework becomes precise only when it maintains a defined material identity, reaches a biologically justified compartment, releases an active payload at the intended place and time, and does so with measurable improvements in exposure, efficacy and safety. This requires a precision-by-design framework that maps claims to minimum evidence and links material critical quality attributes to biological mechanisms, translational assays and development decisions.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1970554"},"PeriodicalIF":4.4,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative evaluation of borneol as a context-dependent modulator of blood-brain barrier function: barrier-restorative or permeability-enhancing agent? 冰片作为血脑屏障功能情境依赖性调节剂的比较评价:屏障恢复剂还是通透增强剂?
IF 4.4
Frontiers in drug delivery Pub Date : 2026-10-09 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1934025
Xiangning Yin, Sarah Ann Thomas
{"title":"Comparative evaluation of borneol as a context-dependent modulator of blood-brain barrier function: barrier-restorative or permeability-enhancing agent?","authors":"Xiangning Yin, Sarah Ann Thomas","doi":"10.3389/fddev.2026.1934025","DOIUrl":"https://doi.org/10.3389/fddev.2026.1934025","url":null,"abstract":"<p><p>The blood-brain barrier (BBB) is an obstacle to effective therapy in neurological disease because it restricts drug access to the brain. Borneol, a lipophilic bicyclic monoterpene used in traditional Chinese medicine, has been associated with opposing effects on BBB function: barrier integrity restoration in ischaemic stroke models and barrier permeability enhancement in drug-delivery models. This mini-review evaluates whether these findings represent a true contradiction or a context-dependent pattern of BBB modulation. The impact of borneol treatment on the intact and damaged barrier was compared by aligning matched readouts within the physical and selective barrier phenotype categories. For example, physical barrier integrity measures explored ionic permeability, tight junction (TJ) organization and macromolecular leakage and selective barrier function measures assessed transcytosis and transport related outcomes. Molecular markers of endothelial state and extracellular matrix integrity were also compared. Across stroke models, borneol was consistently associated with improved barrier resistance, junctional structure preservation and reduced pathological leakage, with the major facilitator superfamily domain-containing protein 2a (Mfsd2a) and caveolin-1 (Cav-1)-mediated transcytosis representing the most clearly defined downstream mechanistic pathway. In delivery models, borneol was associated with transient TEER reduction, TJ protein (claudin-5) redistribution and enhanced tracer or payload passage, consistent with reversible barrier loosening. When these findings were compared through matched readouts, these differences became less contradictory and more conditionally structured. Overall, borneol is better understood as a context-sensitive modulator of BBB function rather than a uniformly barrier-opening or barrier-protective agent. However, translation remains limited by substantial heterogeneity in model, dose and timing, together with unresolved upstream mechanisms.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1934025"},"PeriodicalIF":4.4,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design and optimization of mucoadhesive chitosan microspheres for oesophageal delivery of fluconazole. 食道给药氟康唑用黏附壳聚糖微球的设计与优化。
IF 4.4
Frontiers in drug delivery Pub Date : 2026-10-01 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1962873
H N Shivakumar, Ayush Parmar, Rushikesh Shinde, Sanjana S P
{"title":"Design and optimization of mucoadhesive chitosan microspheres for oesophageal delivery of fluconazole.","authors":"H N Shivakumar, Ayush Parmar, Rushikesh Shinde, Sanjana S P","doi":"10.3389/fddev.2026.1962873","DOIUrl":"10.3389/fddev.2026.1962873","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Oesophageal candidiasis remains challenging to treat owing to rapid transit of conventional oral formulations through the oesophagus, resulting in inadequate local drug delivery and reduced therapeutic efficacy. To address these limitations, the present study aimed to develop fluconazole-loaded chitosan microspheres (FCZ-CMs)-based orodispersible tablets (ODTs) that rapidly disintegrate in the oral cavity while releasing mucoadhesive microspheres capable of adhering to oesophageal mucosa, enabling sustained localized drug delivery.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;FCZ-CMs were developed by the emulsion cross-linking method using a 2&lt;sup&gt;3&lt;/sup&gt; full factorial design to optimize particle size (PS), entrapment efficiency (EE), drug release (DR), and &lt;i&gt;ex vivo&lt;/i&gt; oesophageal retention (ORT). Optimised FCZ-CMs (F9) were extensively characterized by Infrared spectroscopy (FTIR), scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray diffractometry (XRD), and &lt;i&gt;in vitro&lt;/i&gt; drug release studies. Further, the ODTs developed by direct compression of F9 were evaluated for wetting time (WT), disintegration time (DT), drug content (DC), % drug release at 60 min (%DR), similarity (&lt;i&gt;f&lt;/i&gt; &lt;sub&gt;&lt;i&gt;1&lt;/i&gt;&lt;/sub&gt; &lt;i&gt;/f&lt;/i&gt; &lt;sub&gt;&lt;i&gt;2&lt;/i&gt;&lt;/sub&gt; ), and stability under real-time and accelerated conditions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The optimised FCZ-CMs (F9) exhibited a PS (31.81 ± 1.14 μm), EE (84.12% ± 2.15%), DR (58.46% ± 1.89% at 60 min), and ORT (51.22% ± 2.11% at 30 min), demonstrating excellent suitability for localized oesophageal delivery. FTIR confirmed drug-polymer compatibility, SEM revealed spherical microspheres with a crenated surface morphology favourable for mucoadhesion, while DSC and XRD demonstrated reduced crystallinity of FCZ within the chitosan matrix. The ODTs loaded with F9 displayed high DC (99.14% ± 0.58%), short WT (19.62 ± 0.51s), and DT (23.83 ± 0.86s). The dissolution profile of ODTs remained comparable to that of F9 (&lt;i&gt;p &gt; 0.05&lt;/i&gt;), with drug release of 53.16% ± 1.24% at 60 min and similarity factor (&lt;i&gt;f&lt;/i&gt; &lt;sub&gt;&lt;i&gt;2&lt;/i&gt;&lt;/sub&gt; = 80) and difference factor (&lt;i&gt;f&lt;/i&gt; &lt;sub&gt;&lt;i&gt;1&lt;/i&gt;&lt;/sub&gt; &lt;i&gt;= 8&lt;/i&gt;), confirming that the compression process did not significantly alter the release behaviour of the optimised microspheres. The formulation also remained stable under both real-time and accelerated storage conditions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The optimised ODTs successfully translated the performance of FCZ-CMs into a patient-friendly, oesophageal-targeted drug delivery system without compromising their controlled-release or mucoadhesive characteristics. The use of a simple, reproducible, and scalable direct compression process, together with preservation of microsphere functionality following tablet compression, highlights the translational potential of this platform for localized treatment of oesophageal candidiasis and deserves further clinical investigation.&lt;/p","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1962873"},"PeriodicalIF":4.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineering the oxidative myocardium: ROS-responsive biomaterials for precision cardiovascular delivery in ischemia-reperfusion injury and post-infarction remodeling. 氧化心肌工程:用于缺血再灌注损伤和梗死后重构的ros响应生物材料。
IF 4.4
Frontiers in drug delivery Pub Date : 2026-09-16 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1929035
Hossein Omidian, Kwadwo A Mfoafo, Luigi X Cubeddu
{"title":"Engineering the oxidative myocardium: ROS-responsive biomaterials for precision cardiovascular delivery in ischemia-reperfusion injury and post-infarction remodeling.","authors":"Hossein Omidian, Kwadwo A Mfoafo, Luigi X Cubeddu","doi":"10.3389/fddev.2026.1929035","DOIUrl":"10.3389/fddev.2026.1929035","url":null,"abstract":"<p><p>Myocardial ischemia-reperfusion injury (MIRI) and post-infarction remodeling are characterized by dynamic oxidative stress that varies across myocardial regions and disease stages. Reactive oxygen species (ROS)-responsive and redox-modulating biomaterials seek to exploit this environment through stimulus-triggered release or degradation, ROS scavenging, targeted delivery, local retention, and stage-specific repair. This review critically evaluates preclinical strategies for MIRI, myocardial infarction, and post-infarction remodeling. Major platform classes differ substantially in mechanism and translational feasibility: injectable hydrogels offer local retention and spatiotemporal control but often require invasive administration; systemic nanoparticles and liposomes enable tissue-, cell-, or organelle-level targeting but require stronger biodistribution and clearance data; nanozymes provide sustained catalytic redox activity but raise persistence and safety concerns; and cell-, nucleic-acid-, or gas-based systems introduce additional manufacturing and regulatory complexity. Mechanistically, redox interaction represents the initiating action, followed by proximal mitochondrial and cell-death regulation, inflammatory modulation, and later effects on angiogenesis, fibrosis, and ventricular remodeling. Although preclinical studies demonstrate cardioprotective and repair-promoting effects, direct cross-platform comparisons remain limited. Translation is constrained by heterogeneous models, inconsistent definitions of ROS responsiveness, incomplete pharmacokinetic and safety characterization, sparse large-animal validation, and limited manufacturing evidence. ROS-responsive cardiovascular biomaterials therefore remain promising but clinically unproven precision-delivery strategies.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1929035"},"PeriodicalIF":4.4,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: A two-tier protection strategy for oral delivery of GLP-1 peptides: lipid-based formulation combined with enteric capsules. 更正:口服GLP-1肽的两层保护策略:脂基制剂联合肠溶胶囊。
IF 4.4
Frontiers in drug delivery Pub Date : 2026-09-15 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1973549
Camille Dumont, Vanessa Gonzalez, Paula Klatt, Sandrine Picco, Delphine Nombret, Marine Agisson, Euengla Uku, Thibault Saurel, Vincent Jannin
{"title":"Correction: A two-tier protection strategy for oral delivery of GLP-1 peptides: lipid-based formulation combined with enteric capsules.","authors":"Camille Dumont, Vanessa Gonzalez, Paula Klatt, Sandrine Picco, Delphine Nombret, Marine Agisson, Euengla Uku, Thibault Saurel, Vincent Jannin","doi":"10.3389/fddev.2026.1973549","DOIUrl":"https://doi.org/10.3389/fddev.2026.1973549","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fddev.2026.1770094.].</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1973549"},"PeriodicalIF":4.4,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, characterisation, and in vitro assessment of hyaluronic acid-coated solid lipid nanoparticles entrapping dexamethasone palmitate designed for intra-articular administration. 用于关节内给药的透明质酸包被棕榈酸地塞米松固体脂质纳米颗粒的合成、表征和体外评估。
IF 4.4
Frontiers in drug delivery Pub Date : 2026-09-04 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1809275
Jinxin Zhang, Rumi Khandelia, Bridget Hogg, Ahmad Z Bahlool, Tom Hodgkinson, Sally-Ann Cryan, John O'Byrne, David J Brayden
{"title":"Synthesis, characterisation, and <i>in vitro</i> assessment of hyaluronic acid-coated solid lipid nanoparticles entrapping dexamethasone palmitate designed for intra-articular administration.","authors":"Jinxin Zhang, Rumi Khandelia, Bridget Hogg, Ahmad Z Bahlool, Tom Hodgkinson, Sally-Ann Cryan, John O'Byrne, David J Brayden","doi":"10.3389/fddev.2026.1809275","DOIUrl":"10.3389/fddev.2026.1809275","url":null,"abstract":"<p><p>Osteoarthritis (OA) is the major cause of pain and disability worldwide, particularly affecting the knee joint. Although intra-articular (IA) treatments including corticosteroids and hyaluronic acid (HA), are commonly used to manage symptoms, their therapeutic effects are often short-lived, necessitating repeated injections. In this study, HA-coated solid lipid nanoparticles (HA-DXP-SLNs) entrapping with the glucocorticoid prodrug, dexamethasone palmitate (DXP) was developed as dual-function nanocarrier system for IA delivery. Using a scalable microfluidics platform, monodisperse SLNs of ∼90 nm in diameter were produced with high DXP encapsulation efficiency (88%) and loading capacity (6% w/w). In phosphate buffered saline (PBS), DXP-SLNs exhibited a biphasic release profile with an initial burst followed by sustained release of DXP, which was further moderated by HA surface coating. HA coatings of the SLNs enhanced particle stability, shifted particle surface charge from positive to negative, and enabled uptake by patient-derived primary osteoarthritic chondrocytes (hOAAC). Incubation in murine plasma demonstrated enzymatic conversion of DXP to dexamethasone (DEX), which accumulated in plasma over 72 h. HA-DXP-SLNs suppressed prostaglandin E<sub>2</sub> production by LPS-stimulated THP-1 monocytes and by hOAAC more effectively than uncoated DXP-SLNs, while maintaining cell viability. These findings indicate that the HA coating of SLNs contributes to <i>in vitro</i> therapeutic efficacy of the overall SLNs, as well as to particle stabilisation. HA-DXP-SLNs therefore represent a promising nanocarrier for prolonged IA corticosteroid delivery in knee OA, with the potential to reduce the frequency of current IA corticosteroid and HA administration.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1809275"},"PeriodicalIF":4.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13585733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access. 透明质酸酶在基因治疗和再生医学中的增强传递,用于改善载体、细胞和货物的获取。
IF 4.4
Frontiers in drug delivery Pub Date : 2026-09-03 eCollection Date: 2026-01-01 DOI: 10.3389/fddev.2026.1906950
Patrick E Sewell, Christopher Jensen
{"title":"Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access.","authors":"Patrick E Sewell, Christopher Jensen","doi":"10.3389/fddev.2026.1906950","DOIUrl":"10.3389/fddev.2026.1906950","url":null,"abstract":"<p><p>Efficient delivery of gene therapy vectors and regenerative cargo to the central nervous system (CNS) is limited by the hyaluronic acid (HA)-rich extracellular matrix (ECM). Adeno-associated virus (AAV) particles, mesenchymal stem cells (MSCs), multilineage-differentiating stress-enduring (MUSE) cells, and small extracellular vesicles (sEVs) must traverse the HA-rich ECM of the nasal submucosa, the perineural and perivascular compartments, and brain parenchyma to reach CNS targets. Dense ECM imposes viscosity, steric, and hydrodynamic barriers that limit tissue penetration, and perineuronal nets impose an additional HA-based barrier around subsets of neurons. Hyaluronidase enzymes transiently depolymerize HA, reducing tissue viscosity and increasing interstitial permeability through a well-defined, reversible mechanism. Recombinant human hyaluronidase PH20 (rHuPH20) is FDA-approved as a subcutaneous delivery adjunct, demonstrating that controlled ECM modulation is clinically feasible and safe. Preclinical studies demonstrate that hyaluronidase pretreatment enhances intranasal CNS delivery of AAV vectors and sEVs, with quantified improvements in olfactory bulb and cortical distribution. Intranasal MSC and MUSE cell delivery is similarly enhanced: 100 USP units of hyaluronidase applied 30 min before cell administration significantly increased MSC delivery to the olfactory bulb and total brain area in rodent models (p = 0.02). MUSE cells, which express sphingosine-1-phosphate receptor 2 (S1PR2) and home actively to sites of neuroinflammation via the S1P-S1PR2 axis, achieve selective CNS distribution after intranasal administration in Parkinson's disease models, outperforming non-MUSE MSCs and restoring dopaminergic neuron markers and motor function. This narrative review synthesizes the mechanistic basis, evidence tiers, practical intranasal dosing and technique protocols, safety considerations, and translational knowledge gaps for hyaluronidase as a CNS delivery adjunct across viral gene therapy, non-viral platforms, gene-modified cell products, and sEV-based therapeutics. We distinguish established, off-label, and investigational applications, and provide practical guidance for clinicians developing hyaluronidase-augmented CNS programs.</p>","PeriodicalId":73079,"journal":{"name":"Frontiers in drug delivery","volume":"6 ","pages":"1906950"},"PeriodicalIF":4.4,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书